Higher levels of circulating exhausted T-cells at pre- and post-infusion negatively associated with clinical efficacy in tisagenlecleucel (Tisa-cel) treated relapsed/refractory large B-cell lymphoma (r/r LBCL) patients (pts) in JULIET trial.

被引：0
|
作者：
Jaeger, Ulrich [1 ]
Han, Xia [2 ]
Germano, Davide [3 ]
Quinn, David [4 ]
Gaddis, Dalia [5 ]
Masood, Aisha [2 ]
Mulvey, Tanya [4 ]
Mataraza, Jennifer [4 ]
Bishop, Michael R. [6 ]
Salles, Gilles [7 ]
Maziarz, Richard [8 ]
Schuster, Stephen [9 ]
机构：
[1] Med Univ Vienna, Dept Med 1, Clin Div Hematol & Hemostaseol, Vienna Gen Hosp, Vienna, Austria
[2] Novartis Pharmaceut, E Hanover, NJ USA
[3] Novartis Pharma AG, Basel, Switzerland
[4] Novartis Inst BioMed Res, Cambridge, MA USA
[5] Navigate BioPharma Serv, Carlsbad, CA USA
[6] Univ Chicago, David & Etta Jonas Ctr Cellular Therapy, Chicago, IL 60637 USA
[7] Mem Sloan Kettering Canc Ctr, Dept Med, Lymphoma Serv, 1275 York Ave, New York, NY 10021 USA
[8] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA
[9] Univ Penn, Lymphoma Program, Abramson Canc Ctr, Philadelphia, PA 19104 USA
来源：
CANCER RESEARCH | 2022年 / 82卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5186
引用
收藏
页数：2
相关论文
共 27 条
  • [1] COST-EFFECTIVENESS OF AXICABTAGENE CILOLEUCEL (AXI-CEL) AND TISAGENLECLEUCEL (TISA-CEL) IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY (R/R) LARGE B-CELL LYMPHOMA (LBCL) IN CANADA
    Ball, G.
    Kuruvilla, J.
    Boodoo, C.
    Jain, M. D.
    VALUE IN HEALTH, 2021, 24 : S39 - S39
  • [2] Comparative efficacy of tisagenlecleucel (tisa-cel) and lisocabtagene maraleucel (liso-cel) in patients with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL).
    Schuster, Stephen J.
    Zhang, Jie
    Yang, Hongbo
    Agarwal, Abhijit
    Tang, Wenxi
    Martinez-Prieto, Marcela
    Bollu, Vamsi
    Ma, Qiufei
    Kuzan, David
    Maziarz, Richard T.
    Kersten, Marie Jose
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [3] Efficacy and safety of tisagenlecleucel (Tisa-cel) in adult patients (Pts) with relapsed/refractory follicular lymphoma (r/r FL): Primary analysis of the phase 2 Elara trial.
    Schuster, Stephen J.
    Dickinson, Michael J.
    Dreyling, Martin H.
    Martinez, Joaquin
    Kolstad, Arne
    Butler, Jason Paul
    Ghosh, Monalisa
    Popplewell, Leslie
    Chavez, Julio C.
    Bachy, Emmanuel
    Kato, Koji
    Harigae, Hideo
    Kersten, Marie Jose
    Andreadis, Charalambos
    Riedell, Peter A.
    Abdelhady, Ahmed M.
    Zia, Aiesha
    Morisse, Mony Chenda
    Fowler, Nathan Hale
    Thieblemont, Catherine
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [4] Myc Expression and Tumor-Infiltrating T Cells Are Associated with Response in Patients (Pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL) Treated with Tisagenlecleucel in the Juliet Trial
    Jaeger, Ulrich
    Bishop, Michael R.
    Salles, Gilles
    Schuster, Stephen J.
    Maziarz, Richard T.
    Han, Xia
    Savchenko, Alexander
    Roscoe, Nathan
    Orlando, Elena
    Knoblock, Dawson
    Tiwari, Ranjan
    Pacaud, Lida Bubuteishvili
    Corradini, Paolo
    BLOOD, 2020, 136
  • [5] Safety and efficacy of tisagenlecleucel (tisa-cel) plus pembrolizumab (pembro) in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL): Updated analysis of the phase 1b PORTIA study.
    Jaeger, Ulrich
    Worel, Nina
    McGuirk, Joseph
    Riedell, Peter A.
    Fleury, Isabelle
    Borchmann, Peter
    Du, Yan
    Abdelhady, Ahmed M.
    Han, Xia
    Martinez-Prieto, Marcela
    Waller, Edmund K.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [6] Characteristics of Post-Infusion Chimeric Antigen Receptor (CAR) T Cells and Endogenous T Cells Associated with Early and Long-Term Response in Lisocabtagene Maraleucel (liso-cel)Treated Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
    Thorpe, Jerill
    Jiang, Yue
    Rytlewski, Julie A.
    Kostic, Ana
    Kim, Yeonhee
    Peiser, Leanne
    BLOOD, 2021, 138 : 3834 - +
  • [7] Correlative Analyses of Patient and Clinical Characteristics Associated with Efficacy iN Tisagenlecleucel-Treated Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients in the Juliet Trial
    Westin, Jason
    Tam, Constantine
    Borchmann, Peter
    Jaeger, Ulrich
    McGuirk, Joseph
    Holte, Harald
    Waller, Edmund
    Jaglowski, Samantha
    Bishop, Michael
    Andreadis, Charalambos
    Foley, Stephen Ronan
    Fleury, Isabelle
    Ho, P. Joy
    Mielke, Stephan
    Teshima, Takanori
    Schuster, Stephen
    Bachanova, Veronika
    Maziarz, Richard
    Van Besien, Koen
    Izutsu, Koji
    Kersten, Marie Jose
    Magenau, John
    Wagner-Johnston, Nina
    Kato, Koji
    Corradini, Paolo
    Han, Xia
    Tiwari, Ranjan
    Agoulnik, Sergei
    Elderjou, Lamis
    Pacaud, Lida Bubuteishvili
    Salles, Gilles
    BONE MARROW TRANSPLANTATION, 2020, 55 (SUPPL 1) : 48 - 51
  • [8] Correlative Analyses of Patient and Clinical Characteristics Associated with Efficacy in Tisagenlecleucel-Treated Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients in the Juliet Trial
    Westin, Jason R.
    Tam, Constantine S.
    Borchmann, Peter
    Jaeger, Ulrich
    McGuirk, Joseph P.
    Holte, Harald
    Waller, Edmund K.
    Jaglowski, Samantha
    Bishop, Michael R.
    Andreadis, Charalambos
    Foley, Stephen Ronan
    Fleury, Isabelle
    Ho, P. Joy
    Mielke, Stephan
    Teshima, Takanori
    Schuster, Stephen J.
    Bachanova, Veronika
    Maziarz, Richard T.
    Van Besien, Koen
    Izutsu, Koji
    Kersten, Marie Jose
    Magenau, John M.
    Wagner-Johnston, Nina D.
    Kato, Koji
    Corradini, Paolo
    Han, Xia
    Tiwari, Ranjan
    Agoulnik, Sergei
    Eldjerou, Lamis K.
    Pacaud, Lida Bubuteishvili
    Salles, Gilles A.
    BLOOD, 2019, 134
  • [9] Correlative analyses of patient and clinical characteristics associated with efficacy in tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma patients in the JULIET trial
    Westin, J.
    Tam, C. S.
    Borchmann, P.
    Jaeger, U.
    McGuirk, J. P.
    Holte, H.
    Waller, E. K.
    Jaglowski, S.
    Bishop, M. R.
    Andreadis, C.
    Foley, S. R.
    Fleury, I
    Ho, P. J.
    Mielke, S.
    Teshima, T.
    Schuster, S. J.
    Bachanova, V
    Maziarz, R. T.
    Besien, K., V
    Izutsu, K.
    Kersten, M. J.
    Wagner-Johnston, N. D.
    Kato, K.
    Corradini, P.
    Han, X.
    Tiwari, R.
    Eldjerou, L. K.
    Pacaud, L. B.
    Salles, G. A.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 58 - 58
  • [10] Durable Efficacy and Manageable Safety in Patients Aged ≥75 Years With Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL) Treated With Tisagenlecleucel in the Real-World Setting
    Landsburg, Daniel J.
    Heim, Michael
    Moskop, Amy
    Foley, Stephen Ronan
    Hill, Brian T.
    Schofield, Grant
    Jacobson, Caron A.
    Jaglowski, Samantha
    Locke, Frederick L.
    Ram, Ron
    Riedell, Peter A.
    Shah, Gunjan L.
    Popplewell, Leslie L.
    Tiwari, Ranjan
    Lim, Stephen
    Maier, Harald
    Majdan, Marta
    Pasquini, Marcelo C.
    Frigault, Matthew J.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S471 - S471
123